.Pharmacolibrary.Drugs.ATC.D.D11AX22

Information

Ivermectin is a broad-spectrum antiparasitic agent used primarily for the treatment of onchocerciasis (river blindness), strongyloidiasis, and other parasitic infections. It is also approved for the treatment of scabies and certain other ectoparasitic infestations. Ivermectin has been evaluated off-label for a range of other infectious diseases but is primarily used as an antiparasitic agent. It is FDA and EMA approved for parasitic infections in humans.

Pharmacokinetics

Healthy adult volunteers, both sexes, administered a single oral dose of ivermectin.

References

1. Duthaler, U, et al., & Hammann, F (2019). Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. British journal of clinical pharmacology 85(3) 626–633. DOI:10.1111/bcp.13840 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30566757

2. Duthaler, U, et al., & Hammann, F (2020). The effect of food on the pharmacokinetics of oral ivermectin. The Journal of antimicrobial chemotherapy 75(2) 438–440. DOI:10.1093/jac/dkz466 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31691813

3. Fimbo, AM, et al., & Aklillu, E (2023). Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania. CPT: pharmacometrics & systems pharmacology 12(12) 1884–1896. DOI:10.1002/psp4.13038 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37638539

Revisions

• 06/2025 initial generated model